Concord Drugs Ltd
Incorporated in 1995, Concord Drugs Ltd manufactures licensed drugs based on
approved formulations
- Market Cap ₹ 101 Cr.
- Current Price ₹ 76.7
- High / Low ₹ 92.5 / 56.0
- Stock P/E 49.3
- Book Value ₹ 36.8
- Dividend Yield 0.00 %
- ROCE 5.51 %
- ROE 2.57 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is expected to give good quarter
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding has decreased over last quarter: -9.31%
- Company has a low return on equity of 1.73% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|
| 58.96 | 52.08 | 44.92 | 45.24 | 78.77 | 86.12 | |
| 53.37 | 47.51 | 40.88 | 41.10 | 74.22 | 80.29 | |
| Operating Profit | 5.59 | 4.57 | 4.04 | 4.14 | 4.55 | 5.83 |
| OPM % | 9.48% | 8.77% | 8.99% | 9.15% | 5.78% | 6.77% |
| 0.10 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | |
| Interest | 1.68 | 1.71 | 1.87 | 2.03 | 1.71 | 1.63 |
| Depreciation | 1.76 | 1.63 | 1.56 | 1.43 | 1.37 | 1.35 |
| Profit before tax | 2.25 | 1.24 | 0.62 | 0.69 | 1.47 | 2.85 |
| Tax % | 28.89% | 20.97% | 25.81% | 50.72% | 28.57% | |
| 1.59 | 0.99 | 0.47 | 0.34 | 1.06 | 2.05 | |
| EPS in Rs | 1.82 | 1.06 | 0.47 | 0.34 | 0.80 | 1.60 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 15% |
| TTM: | 83% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 2% |
| TTM: | 377% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 24% |
| 3 Years: | 29% |
| 1 Year: | 43% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 3% |
| 3 Years: | 2% |
| Last Year: | 3% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Equity Capital | 8.74 | 9.32 | 10.00 | 10.00 | 13.18 |
| Reserves | 19.62 | 22.38 | 23.82 | 24.11 | 35.34 |
| 16.43 | 16.96 | 17.52 | 19.24 | 13.60 | |
| 11.66 | 9.57 | 7.46 | 11.80 | 12.77 | |
| Total Liabilities | 56.45 | 58.23 | 58.80 | 65.15 | 74.89 |
| 13.97 | 12.92 | 11.68 | 12.21 | 11.58 | |
| CWIP | 0.55 | 0.92 | 1.63 | 2.00 | 2.43 |
| Investments | 0.00 | 0.89 | 0.84 | 0.80 | 0.78 |
| 41.93 | 43.50 | 44.65 | 50.14 | 60.10 | |
| Total Assets | 56.45 | 58.23 | 58.80 | 65.15 | 74.89 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| 0.77 | 1.66 | 0.79 | 3.72 | -6.77 | |
| -2.44 | -2.27 | -1.01 | -2.32 | -1.13 | |
| 1.68 | 0.62 | 0.28 | -1.43 | 8.06 | |
| Net Cash Flow | 0.01 | 0.02 | 0.07 | -0.02 | 0.16 |
| Free Cash Flow | -1.69 | 0.80 | -0.23 | 1.39 | -7.94 |
| CFO/OP | 26% | 45% | 25% | 95% | -140% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor Days | 141.52 | 110.80 | 103.44 | 109.73 | 112.97 |
| Inventory Days | 151.64 | 178.58 | 251.53 | 261.81 | 137.69 |
| Days Payable | 62.25 | 46.92 | 34.02 | 78.95 | 38.15 |
| Cash Conversion Cycle | 230.90 | 242.47 | 320.95 | 292.59 | 212.52 |
| Working Capital Days | 112.48 | 152.43 | 132.77 | 115.78 | 145.92 |
| ROCE % | 6.31% | 4.98% | 5.20% | 5.51% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Capital Expenditure on Fixed Assets Rs. Lakhs ・Standalone data |
|
|||||||||
| Purchases from Related Parties Rs. Lakhs ・Standalone data |
||||||||||
| Sales to Related Parties Rs. Lakhs ・Standalone data |
||||||||||
| Number of Employees count ・Standalone data |
||||||||||
| Capital Work-in-Progress Rs. Lakhs ・Standalone data |
||||||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Copy of News-paper publications for quarterly results ended 30th June 2026.
-
Financial Results For Quarter Ended 30 June 2026
- Concord Drugs approved Q1 FY27 unaudited results; standalone profit rose to Rs111.23 lakh on Rs2,088.86 lakh revenue.
-
Board Meeting Outcome for Outcome Of Board Meeting
- Board approved Q1 FY27 standalone and consolidated results on 10 Aug 2026; standalone profit rose to Rs111.23 lakh.
-
Board Meeting Intimation for Quarterly Results
- Board meeting on 10 August 2026 to approve Q1 FY2026-27 standalone and consolidated results.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
- Submitted Regulation 74(5) certificate for quarter ended 30 June 2026.
Annual reports
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
Business Overview:[1]
CDL is a Telangana based company which is in the business of manufacturing licensed bulk drugs and active pharmaceutical intermediates on the approved formulations. Company started with Finished Pharmaceutical Formulations and then diversified into Ready-to-fill Pellets, to provide customers with end-to-end solution to their various pharmaceutical product needs to commercial contract drug manufacturing.